The devastating AIDS crisis of the 1980s and 1990s left a tragic legacy of loss, but it also gave rise to a little‑known financial market that thrives on predicting the lifespan of terminally ill patients. As mortality rates surged, insurers, hedge funds, and specialty investors began creating securities tied to the life expectancy of individuals diagnosed with HIV/AIDS. These instruments—often packaged as life‑settlement bonds or mortality swaps—allowed investors to profit from the probability of early death, turning human suffering into a tradable commodity. The market grew to an estimated $10 billion in value before advances in antiretroviral therapy dramatically extended life spans, prompting regulators to scrutinize the ethical implications and push for stricter disclosure rules. Advocates argue that the industry exploits vulnerable populations, while some financial analysts claim it provides liquidity for families facing costly medical bills.
On top of everything as it happens